ADAGNasdaqPharmaceutical PreparationsUS GAAP · USD

Adagene Inc.

Adagene Inc. is a biotechnology company focused on discovering and developing antibody-based cancer therapies. It operates through a network of subsidiaries across the United States, China, Hong Kong, Australia, Singapore, and Switzerland, and its shares trade on Nasdaq through ADSs.

Kysy yhtiöstä
Liikevaihto7,7milj. USD
+7 332,8 %v/v
Liikevoitto (EBIT)−21,4milj. USD
+40,4 %v/v
EBIT-marginaali−279,5%
+34 555,9 %-yks.v/v
Nettotulos−17,6milj. USD
+47,3 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100−75−50−25025milj. USD2020: 0,70 milj. USD2020: EBIT −43 milj. USD20202021: 10 milj. USD2021: EBIT −72 milj. USD20212022: 9,3 milj. USD2022: EBIT −84 milj. USD20222023: 18 milj. USD2023: EBIT −24 milj. USD20232024: 0,10 milj. USD2024: EBIT −36 milj. USD20242025: 7,7 milj. USD2025: EBIT −21 milj. USD20257,7−21
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Platform technology licensing50 %

Licensing of the SAFEbody technology platform for use in masked antibody and ADC programs.

Clinical oncology candidates35 %

Company-owned therapeutic programs in clinical and preclinical development for cancer indications.

Research and discovery services15 %

Collaborative discovery, engineering, and preclinical development work for partners.

Asiakkaat

Adagene’s customers and partners are mainly biopharmaceutical companies that license its antibody engineering technology or co-develop oncology candidates. Its therapeutic programs are ultimately designed for cancer patients, but commercial value is created through collaborations with drug developers that fund and advance development. The company also works with scientific and clinical research ecosystems supporting antibody discovery and translational oncology.

Pharmaceutical collaboration partners

License SAFEbody and co-develop masked antibody and ADC programs.

Oncology drug developers

Partner on preclinical and clinical programs to access Adagene's platform.

Clinical research networks

Run trials and provide data for the company’s cancer candidates.

Patients with solid tumors

End users of the therapies being developed for cancer treatment.

Strategia

Adagene’s strategy is centered on advancing SAFEbody as a differentiated masking platform for antibody and ADC programs. It uses partnerships to extend the technology into multiple programs while continuing to move its own oncology candidates through clinical development. The model depends on translating platform validation into milestone payments, development progress, and eventual royalties or product value.

Validate SAFEbody through partnershipsLyhyt aikaväli

Partner programs can prove the platform and create milestone/royalty economics.

Advance clinical oncology pipelineKeskipitkä aikaväli

Clinical data are needed to support future partnering, value creation, and potential commercialization.

Expand application of masking technologyKeskipitkä aikaväli

Broader use cases increase the addressable partner pipeline and platform relevance.

Maantiede

Adagene is headquartered in the Cayman Islands structure, with operational and scientific presence centered in Suzhou, China and San Diego, United States. Its subsidiary footprint also spans Hong Kong, Australia, Singapore, and Switzerland, reflecting a cross-border research and partnering model. The business is globally oriented because licensing and clinical development collaborations can involve partners and trial activity across multiple regions.

Riskit

Adagene is exposed to clinical development risk, because its value depends on whether its oncology candidates show acceptable efficacy and safety in trials. It also faces partner concentration and execution risk, since milestones and royalties depend on collaborators advancing programs, and biotech funding/valuation can be highly sensitive to data readouts. As a global developer with operations in the U.S. and China, it also faces cross-border regulatory, foreign exchange, and localization risks.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical failure of oncology candidates1Partner dependency2Regulatory and cross-border execution3Foreign exchange volatility4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical failure of oncology candidatesVaikutus: KriittinenTodennäköisyys: Korkea

    Pipeline value depends on trial results, and early-stage oncology programs can fail at efficacy or safety readouts.

    Kohdistuu: Muzastotug and other pipeline assets

  2. Partner dependencyVaikutus: KorkeaTodennäköisyys: Korkea

    Milestone and royalty revenue rely on collaborators continuing development and selecting programs.

    Kohdistuu: SAFEbody collaboration agreements

  3. Regulatory and cross-border executionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Drug development requires approvals and trial execution across jurisdictions with different requirements.

    Kohdistuu: United States and China operations

  4. Foreign exchange volatilityVaikutus: KeskitasoTodennäköisyys: Korkea

    Operating cash flows and reported results are affected by multiple currencies across subsidiaries.

    KohdistuuUSDRMBHKDSGDCHFAUD

Kirjanpito

Harkinnanvaraiset erät
Licensing and collaboration revenue

Milestone-based contracts require judgment on when obligations are satisfied and revenue can be recognized.

Vaikutus: Affects the timing and volatility of reported revenue.

Fair value of warrant liabilities

Derivative liabilities are remeasured, creating non-cash gains or losses in the income statement.

Vaikutus: Can materially change net loss period to period.

Foreign currency translation

Multi-currency subsidiaries create translation adjustments in comprehensive income.

Vaikutus: Affects equity and comprehensive loss, especially with RMB and USD movements.

Research and development capitalization policy

Biotech spending is largely expensed as incurred, shaping the scale of operating loss.

Vaikutus: Directly drives operating expense trends as programs advance.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Adlai Nortye Group Ltd.

ANL · Pharmaceutical Preparations

Jade Biosciences, Inc.

JBIO · Pharmaceutical Preparations

Immunome Inc.

IMNM · Pharmaceutical Preparations

Compugen Ltd

CGEN · Biological Products, (No Diagnostic Substances)

Exagen Inc

XGN · Services-Medical Laboratories

Whitehawk Therapeutics, Inc.

WHWK · Pharmaceutical Preparations

Päivitetty: 28.9.2026

Adagene Inc. (Nasdaq) – Pharmaceutical Preparations | Analyysi – Clarifo